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m103451 IssP~ theOptimalBiologicalTestto EvaluateAnticoagulantEfficacyof HeparinGivenas
AdjunctiveTherapytoThrombolysis?
A. Vuillemenot, N. Meneveeu, F. Schiele, T.Jdcques, T.Anguenot,
Y. Bernard, J.-P. Bsssand. F@ital Univemitaire Sairrt-Jacques,25000
Besen~on, France
There are some evidence that aPTT could be influenced by thrombolyfics,
so that aPTT may not adequately reflect the level of anticoagulation. The
aim of this study was to verify if aPTT ratio between 1.5 to 2.5 achieved by
heparin given as adjunctive therapy to thrombolytics actually corresponds to
an anti-Xa activity therapeutic range of 0.35 to 0.70 U/mL. aPTT, anti-Xa,
fibrinogen (g/l) and FDP (pglml) were evaluated 6, 12, 18, 24, 36 and 46 h
after rt-PA and heparin in 14 pta. aPTT and anti-Xa activity were concordant
(both under, within or beyond their own therapeutic range) in only 44% of
the samplea. The discrepancy between anti-Xa activity and aPTT was more
pronounced within the first 24 h where as many se 64% of the results were
discordant.
aPTr and anti-Xa 24 hours 48 hours FDP Fg
Concordant 36% 46% 4582 3.62
Discordant 84% 52% 9315’ 2.84
In most of the discordant results (98%), aPTT was overestimated with re-
gard to anti-Xa activity. FDP levels were significantly higher in the discordant
than in the concordant group (*p = 0.04). These results suggest that aPTT
determination was influenced by thrombolytic therapy, and was shown to
overestimate antiooagulation efficacy parficulaty during the first 24 hrs after
thrombolytics, period during which reooclusion rate is at its maximum. Thus
aPTT can be misleading in monitoring anticoegulation in this issue.
m103452 TreatmentRoutines and Mortality in AcuteMyocardial Infarction - A Comparison Between
Minneapolis-St. ”Paul,USA and Goteborg, Sweden
J. Herlitz, P. McGovern ~,J. Pankowl, R.V. Luepker. Sah/grenaka Univ.
Hosp., Gdteborg, Sweden, 1>fhiv. of Minnesota, Ml, USA
Aim: To compare the treatment routines and morIality during one year of
follow-up in acute myocardial infarction (AMI) between Minneapolis-St. Paul
(MP) and Goteborg (G).
Methods: In 199C-91 50% of patients (pta) hospitalized in MP and all pts
hospitalized in G with diacharge diagnosis ICD9 410 were included if aged
30-74 years and living in the community. All data were age adjusted.
Results (%):
Women Men
MP G P MP G P
n. s32 n. 295 n = 1055 n = 603
Treatment in hospital:
Thrombolytictherapy 22 32 <0.01 32 36 <0.01
PTCA 14 3 <0.01 20 5
CABG
<0.01
11 1 <0.01 12 1 <0.01
Bstsblockers 39 76 <0.01 50 88 <0.01
Calciumchannel blocksrs 63 17 <0.01 59 ta <0.01
Lidocaine 47 8 <0,01 57 11 <0.01
Aspirin 70 72 NS 81 80 NS
Iv, nitroglyc, 60 29 <0,01 67 3s <0.01
1yssrmortality:
All pts 22 23 NS 17 21 0.02
Fls treatsd in CCUIICU 17 16 NS 19 22 NS
ValidatedAMI 21 16 NS 14 12 NS
Conclusion: Marked differences in the earfy treatment of AMI are found
between MP and G. However, mortality appears to be similar.
-] WfeightAdjW3tedAntithrombotic Regimens
Eliminate the Nitroglycerin-Antithrombotic
Interaction
D.A. Vorchheimer, L, Baruch, E.T. DePeralta, I.C. Guzman, R.M. Hayea,
AS. Hellkamp, C.B. Granger, E.J. Topol, R.M. Califf for the GUSTO-llb
Investigators. Cardiovascular hrstitute, Mount Sinai Medical CenteCNew
York,NY USA, Duke Clinical Research Institute, Durham, NC, USA
When intravenous (IV) nitroglycerin (NTG) is added toantithrombotic therapy
for patients (pts) with acute coronary syndromes, attenuation of the antico-
agulant effect has been reported: PTTs are lower in pts receiving IV NTG +
heparin (HEP) than in pts receiving IV HEPalone. In GUSTO-llb, IV HEP and
hirudin (HIR) were given according to a strict weight adjusted nomogram,
We studied PTTs(see + SEM) adjusted for weight in pts who did (NTG+)
or did not (NTG–) receive IV NTG. No consistent effect of NTG was seen for
the study group as a whole (although l p <0.05, NTG+ vs. NTG- for day 2
Pl_T)nor for either HEP or HIR. However, NTG+ pts required more frequent
changes in study drug infusion rate with both HEP (4.58 vs. 4.01) and HIR
(2.56 vs. 2.10, both p = 0.0001), suggesting that while NTG may well interact
with an antithrombotic regimen, the clinical impact of such an effect can be
overcome by rigorous adherence to a dosing nomogram.
NTG+ (n = 9281) NTG– (n= 2961)
Weight (kg) 77.84 & 0.16 77.46 & 0,26
Bas;lini ~ti 33.58 * 0.40 34.51 + 0.53
6 hourPTr 91.09+ 2.41 67,85 & 0,67
12 hourPIT 75.31 * 0.35 75.26+ 0.60
24 hourPIT 68.47 + 0.31 68.42 + 0.51
dav 2 PIT 6S.29 + 0.29 70.S6+ 0.49*
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Bedside During Thrombolytic Therapy for Acute
Myocardial Infarction
K. Al Shwafi, J. Col, B. Pirenne, A. de Meester, C. Miesse, J. Renkin.
University of Louvain Medical School, Brussels, Belgium
Establishing and maintaining a l~ic activity (LA) after administration of a
thrombolyfic agent is affected by any or all of the fibrinolytic factors and
inhibitors. Accelerated t-PA regimen is considered as the most effective
thrombolytic regimen in AMI. Currently, no practical assays are available for
rapid determination of whole blood LA during thrombolytic therapy. A new
bedside card method that measures Iysis onset time (LOT) using clot Iyais
as endpoint was developed as part of the Thrombolytic Assessment System
(TAS), results being available within few minutes. To characterize the Iytic
activity induced by accelerated t-PA infusion, we measured LOT at baaeline,
5-10 min post bolus, end of inf (90 rein) and 180 min in 80 AMI patients (62
+12 yre, 82% male). The existence of LA was considered when LOTs 121XI
seconds. Results are median (25th-75th percentile).
Baseline 10 min 90 min 180 min
LOT (see) >1200 13s 169 >1200
LOT (secj (> 1200-> 1200) (132-146) (147-218) >1200 (904-> 1200)
LA detected (OApts) O 100 96 26
Conclusion: (1) LOT determination demonstrated fast establishment of
Iytic activity after the bolus in all pts and confirmed that t-PA infusion main-
tained efficient LA in most pts, which weaned rapidly after end of infusion.
(2) Characterization of LOT response with the TAS card method explains
the efficacy of the accelerated t-PA regimen against which other thrombolytic
regimens should be compared.
D103455 ST-SegmentRecoveryParametersPredictiveofOutcomein AMI: Variability with Infarct Artery
Location and Implications for Therapeutic Targets
M.W. Kruooff, C.L. Green, K.M. Trollinger, J.E. Pope, C.B. Granger, E.M.
Ohman, R.M. Califf. Duke University Medical Center, Durham, NC, USA
Mechanisms of coronary occlusion and response to reperfusion therapies
may vary in different epicardial infarct arteries (IRA). Blinded ST-core lab
analysis of continuous 12-lead ECG recordings in 617 pts. with AMI given
l~ics in the TAMI-9 (n = 23$), DUCCS-2 (n= 36), GUSTO-1 (n= 224), and
IMPACT-I(n= 119)studies were stratified by blinded angio-core lab IRA (230
LAD, 287 RCA, 80 CIRC & 20 OTHER). 12-lead ST recovery parameters
predictive of clinical OUTCOMES defined as s 30 day CHF or death were:
PEAK ST deviation (uV): time from l~ics to STEADY ST recove~ of > 50%
of PEAK for > 4 hours (rein); rapid ST recovery and re-elevation before
STEADY recovery suggesting CYCLIC changes in IRA flow; LATE ST re-
